Trial Profile
Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2015
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Biomarker; Therapeutic Use
- 16 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.